<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6785">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018587</url>
  </required_header>
  <id_info>
    <org_study_id>C-16-TS12</org_study_id>
    <nct_id>NCT03018587</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the TruSculpt Radiofrequency Device</brief_title>
  <official_title>Feasibility Study of the TruSculpt Radiofrequency Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center, prospective, open-label feasibility study of the truSculpt radiofrequency
      device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, prospective, open-label study to evaluate the safety and efficacy of the
      Cutera truSculpt radiofrequency device for optimal delivery of thermal energy to the skin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of improvement in the treatment area at 12 weeks post-treatment as assessed by the Investigator.</measure>
    <time_frame>At 12 weeks post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of improvement at 12 weeks post-treatment</measure>
    <time_frame>At 12 weeks post-treatment</time_frame>
    <description>Subject will complete a questionnaire to asses improvement of treated area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction level at 12 weeks post-treatment</measure>
    <time_frame>At 12 weeks post-treatment</time_frame>
    <description>Subject will complete a questionnaire to asses treatment satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject pain levels during treatment</measure>
    <time_frame>Within 5 to 10 minutes post-treatment</time_frame>
    <description>Using a numeric scale of 0 to 10, subject's will be asked to rate the average level of pain experienced during treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tissue Tightening</condition>
  <arm_group>
    <arm_group_label>TruSculpt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject(s) will receive 1 radio frequency treatment in desired area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TruSculpt</intervention_name>
    <description>Subject(s) will receive 1 Trusculpt (Radio Frequency) Device Treatment</description>
    <arm_group_label>TruSculpt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female, 24 to 65 years of age (inclusive)

          2. Fitzpatrick Skin Type I - VI

          3. Has visible fat bulges or skin laxity in the treatment area

          4. Non-smoking for at least 6 months and willing to refrain from smoking for the
             duration of the study.

          5. Subject must agree to not undergo any other procedure(s) in the submental region
             during the study period.

          6. Subject must be able to read, understand and sign the Informed Consent Form.

          7. Subject must adhere to the follow-up schedule and study instructions.

          8. Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation, educational or marketing purposes.

          9. Post-menopausal or surgically sterilized, or using a medically acceptable form of
             birth control at least 3 months prior to enrollment and during the entire course of
             the study, and no plans to become pregnant.

        Exclusion Criteria:

          1. Participation in a clinical trial of another device or drug in the target area during
             the study period.

          2. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator,
             nerve stimulator implant, cochlear implant or any other electronically, magnetically
             or mechanically activated implant.

          3. Has metal implant(s) within the body, such as surgical clips, plates and screws,
             intrauterine device (IUD), artificial heart valves or artificial joints.

          4. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease,
             peripheral vascular disease or pertinent neurological disorders.

          5. Diagnosed or documented immune system disorders.

          6. History of any disease or condition that could impair wound healing.

          7. History of diseases stimulated by heat, such as recurrent herpes zoster in the
             treatment area, unless treatment is conducted following a prophylactic regimen.

          8. Infection, dermatitis, rash or other skin abnormality in the target area.

          9. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or
             history of treatment in the target area within 3 months of study participation.

         10. Pregnant or currently breastfeeding.

         11. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ronan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Hammond</last_name>
    <phone>4156575538</phone>
    <email>mhammond@cutera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Hu</last_name>
    <phone>4156575543</phone>
    <email>ehu@cutera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cutera Research Center</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Jay</last_name>
      <phone>415-657-5749</phone>
      <email>jjay@cutera.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Ronan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>January 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>None. No individual participant data will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
